Relmada Therapeutics, Inc.
RLMD
$7.49
$0.040.54%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -6.49% | 53.55% | 44.47% | 19.56% | 25.86% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -38.93% | -52.26% | -51.73% | -47.97% | -26.58% |
| Change in Net Operating Assets | -64.82% | 90.98% | 100.95% | -895.25% | -46.73% |
| Cash from Operations | -65.87% | 59.64% | 51.73% | -38.59% | 14.15% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -778.07% | -58.17% | -52.35% | 52.70% | 46.56% |
| Cash from Investing | -778.07% | -58.17% | -52.35% | 52.70% | 46.56% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 100.00% | 100.00% | -- | -- | -75.13% |
| Cash from Financing | 54,382.78% | 100.00% | -- | -- | -75.13% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -11.00% | 105.16% | -72.90% | 1.79% | 191.03% |